阻塞性睡眠呼吸暂停低通气综合征与糖脂代谢紊乱的机制研究进展

doi:10.12114/j.issn.1007-9572.2021.01.311

摘要/Abstract

摘要： 阻塞性睡眠呼吸暂停低通气综合征（OSAHS）是以呼吸暂停、低通气、血氧饱和度下降及睡眠结构紊乱为特征的一种疾病，是心血管疾病的严重危险因素。近年来研究发现，OSAHS患者合并高血压、冠状动脉粥样硬化性心脏病、胰岛素抵抗、2型糖尿病、代谢综合征、非酒精性脂肪肝等疾病的发病率增加。诸多研究显示，OSAHS患者常存在明显的糖脂代谢紊乱，并在心血管疾病的发病率、死亡率中扮演着重要角色。因此，本文从OSAHS与糖脂代谢的关系入手，从病因学层面，就OSAHS引起糖脂代谢紊乱及胰岛素抵抗的机制作一综述，以期为临床治疗提供新的思路。

关键词: 睡眠呼吸暂停, 阻塞性, 阻塞性睡眠呼吸暂停低通气综合征, 糖代谢, 脂代谢, 胰岛素抵抗, 心血管疾病, 综述

Abstract:

Obstructive sleep apnea-hypopnea syndrome (OSAHS) is a disease marked by apnea, hypopnea, decreased oxygen saturation, and disordered sleep structure, which is a major risk for cardiovascular disease. Recent studies have found that OSAHS patients have an increased risk of hypertension, coronary atherosclerotic heart disease, insulin resistance, type 2 diabetes, metabolic syndrome, non-alcoholic fatty liver disease, etc. And these patients have a high prevalence of obvious glucolipid metabolism disorder (GMD) , which plays an important role in cardiovascular morbidity and mortality in OSAHS. We reviewed the latest advances in the association of GMD and OSAHS, and the potential pathogenesis of OSAHS-induced GMD and insulin resistance, aiming at providing new ideas for clinical treatment of GMD in OSAHS.

Key words: Sleep apnea, obstructive, OSAHS, Glucose metabolism, Lipid metabolism, Insulin resistance, Cardiovascular diseases, Review

中图分类号:

R749.79R563.8

王云,何燕,刘师节,等. 阻塞性睡眠呼吸暂停低通气综合征与糖脂代谢紊乱的机制研究进展[J]. 中国全科医学, 2022, 25(02): 243-247. DOI: 10.12114/j.issn.1007-9572.2021.01.311.

WANG Yun, HE Yan, LIU Shijie, GAN Lulu, GAO Huifang, LIANG Min, ZUO Zhiheng, YANG Li.

Recent Advances in the Pathogenesis of Glucolipid Metabolism Disorder in Obstructive Sleep Apnea-hypopnea Syndrome [J]. Chinese General Practice, 2022, 25(02): 243-247.

参考文献 38

[1]	PEPPARD P E，YOUNG T，BARNET J H，et al. Increased prevalence of sleep-disordered breathing in adults[J]. Am J Epidemiol，2013，177（9）：1006-1014. DOI：10.1093/aje/kws342.
[2]	DRAGER L F，POLOTSKY V Y，DONNELL C P，et al. Translational approaches to understanding metabolic dysfunction and cardiovascular consequences of obstructive sleep apnea[J]. Am J Physiol Heart Circ Physiol，2015，309（7）：H1101-1111. DOI：10.1152/ajpheart.00094.2015.
[3]	LAVIE L，VISHNEVSKY A，LAVIE P. Evidence for lipid peroxidation in obstructive sleep apnea[J]. Sleep，2004，27（1）：123-128.
[4]	SONG S O，HE K，NARLA R R，et al. Metabolic consequences of obstructive sleep apnea especially pertaining to diabetes mellitus and insulin sensitivity[J]. Diabetes Metab J，2019，43（2）：144-155. DOI：10.4093/dmj.2018.0256.
[5]	BARROS D，GARCÍA-RÍO F. Obstructive sleep apnea and dyslipidemia：from animal models to clinical evidence[J]. Sleep，2019，42（3）：zsy236. DOI：10.1093/sleep/zsy236.
[6]	SAVRANSKY V，JUN J，LI J，et al. Dyslipidemia and atherosclerosis induced by chronic intermittent hypoxia are attenuated by deficiency of stearoyl coenzyme A desaturase[J].Circ Res，2008，103（10）：1173-1180. DOI：10.1161/circresaha.108.178533.
[7]	YUAN G，NANDURI J，BHASKER C R，et al. Ca2+/calmodulin kinase-dependent activation of hypoxia inducible factor 1 transcriptional activity in cells subjected to intermittent hypoxia[J].J Biol Chem，2005，280（6）：4321-4328. DOI：10.1074/jbc.m407706200.
[8]	SANZ-RUBIO D，SANZ A，VARONA L，et al. Forkhead box P3 methylation and expression in men with obstructive sleep apnea[J].Int J Mol Sci，2020，21（6）：E2233. DOI：10.3390/ijms21062233.
[9]	SUN Z，SHEN W. Effect of intermittent hypoxia on lipid metabolism in liver cells and the underlying mechanism[J]. Chinese Journal of Hepatology，2014，22（5）：369-373. DOI：10.3760/cma.j.issn.1007-3418.2014.05.010.
[10]	PARIKH M P，GUPTA N M，MCCULLOUGH A J. Obstructive sleep apnea and the liver[J].Clin Liver Dis，2019，23（2）：363-382. DOI：10.1016/j.cld.2019.01.001.
[11]	YUAN H B，SCHWAB R J，KIM C，et al. Relationship between body fat distribution and upper airway dynamic function during sleep in adolescents[J]. Sleep，2013，36（8）：1199-1207. DOI：10.5665/sleep.2886.
[12]	BOZKURT N C，BEYSEL S，KARBEK B，et al. Visceral obesity mediates the association between metabolic syndrome and obstructive sleep apnea syndrome[J]. Metab Syndr Relat Disord，2016，14（4）：217-221. DOI：10.1089/met.2015.0086.
[13]	LAFONTAN M，LANGIN D. Lipolysis and lipid mobilization in human adipose tissue[J]. Prog Lipid Res，2009，48（5）：275-297. DOI：10.1016/j.plipres.2009.05.001.
[14]	XIONG Y L，QU Z，CHEN N，et al. The local corticotropin-releasing hormone receptor 2 signalling pathway partly mediates hypoxia-induced increases in lipolysis via the cAMP-protein kinase A signalling pathway in white adipose tissue[J]. Mol Cell Endocrinol，2014，392（1/2）：106-114. DOI：10.1016/j.mce.2014.05.012.
[15]	YUAN H B，SCHWAB R J，KIM C，et al. Relationship between body fat distribution and upper airway dynamic function during sleep in adolescents[J]. Sleep，2013，36（8）：1199-1207. DOI：10.5665/sleep.2886.
[16]	LI M，LI X Y，LU Y. Obstructive sleep apnea syndrome and metabolic diseases[J]. Endocrinology，2018，159（7）：2670-2675. DOI：10.1210/en.2018-00248.
[17]	FU C，JIANG L，ZHU F，et al. Chronic intermittent hypoxia leads to insulin resistance and impaired glucose tolerance through dysregulation of adipokines in non-obese rats[J]. Sleep Breath，2015，19（4）：1467-1473. DOI：10.1007/s11325-015-1144-8.
[18]	ULUKAVAK CIFTCI T，KOKTURK O，BUKAN N，et al. Leptin and ghrelin levels in patients with obstructive sleep apnea syndrome[J]. Respiration，2005，72（4）：395-401. DOI：10.1159/000086254.
[19]	MOREAU J M，MESSENGER S A，CIRIELLO J. Effects of angiotensin II on leptin and downstream leptin signaling in the carotid body during acute intermittent hypoxia[J]. Neuroscience，2015，310：430-441. DOI：10.1016/j.neuroscience.2015.09.066.
[20]	CHEN B Y，LAM K S，WANG Y，et al. Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes[J]. Biochem Biophys Res Commun，2006，341（2）：549-556. DOI：10.1016/j.bbrc.2006.01.004.
[21]	POLYZOS S A，KOUNTOURAS J，MANTZOROS C S. Adipokines in nonalcoholic fatty liver disease[J]. Metabolism，2016，65（8）：1062-1079. DOI：10.1016/j.metabol.2015.11.006.
[22]	GREENHILL C. Obesity：Adiponectin receptor agonists——possible therapeutic approach？[J]. Nat Rev Endocrinol，2014，10（1）：4. DOI：10.1038/nrendo.2013.231.
[23]	OUCHI N，HIGUCHI A，OHASHI K，et al. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity[J]. Science，2010，329（5990）：454-457. DOI：10.1126/science.1188280.
[24]	SUN S，ZHAI H，ZHU M，et al. Insulin resistance is associated with Sfrp5 in obstructive sleep apnea[J]. Braz J Otorhinolaryngol，2019，85（6）：739-745. DOI：10.1016/j.bjorl.2018.07.002.
[25]	POLAK J，SHIMODA L A，DRAGER L F，et al. Intermittent hypoxia impairs glucose homeostasis in C57BL6/J mice：partial improvement with cessation of the exposure[J]. Sleep，2013，36（10）：1483-1490；1490A-1490B. DOI：10.5665/sleep.3040.
[26]	XIA Q S，LU F E，WU F，et al. New role for ceramide in hypoxia and insulin resistance[J]. World J Gastroenterol，2020，26（18）：2177-2186. DOI：10.3748/wjg.v26.i18.2177.
[27]	BROUSSARD J，BRADY M J. The impact of sleep disturbances on adipocyte function and lipid metabolism[J]. Best Pract Res Clin Endocrinol Metab，2010，24（5）：763-773. DOI：10.1016/j.beem.2010.08.007.
[28]	NONOGAKI K. New insights into sympathetic regulation of glucose and fat metabolism[J]. Diabetologia，2000，43（5）：533-549. DOI：10.1007/s001250051341.
[29]	KUMAR G K，RAI V，SHARMA S D，et al. Chronic intermittent hypoxia induces hypoxia-evoked catecholamine efflux in adult rat adrenal medulla via oxidative stress[J]. J Physiol，2006，575（Pt 1）：229-239. DOI：10.1113/jphysiol.2006.112524.
[30]	BODEN G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver[J]. Curr Diab Rep，2006，6（3）：177-181. DOI：10.1007/s11892-006-0031-x.
[31]	MESARWI O A，SHARMA E V，JUN J C，et al. Metabolic dysfunction in obstructive sleep apnea：a critical examination of underlying mechanisms[J]. Sleep Biol Rhythms，2015，13（1）：2-17. DOI：10.1111/sbr.12078.
[32]	GAINES J，VGONTZAS A N，FERNANDEZ-MENDOZA J，et al. Obstructive sleep apnea and the metabolic syndrome：The road to clinically-meaningful phenotyping，improved prognosis，and personalized treatment[J]. Sleep Med Rev，2018，42：211-219. DOI：10.1016/j.smrv.2018.08.009.
[33]	ZHAO L，LIU Y，WANG X R. TNF-α promotes insulin resistance in obstructive sleep apnea-hypopnea syndrome[J]. Exp Ther Med，2021，21（6）：568. DOI：10.3892/etm.2021.10000.
[34]	LEE E J，HEO W，KIM J Y，et al. Alteration of inflammatory mediators in the upper and lower airways under chronic intermittent hypoxia：preliminary animal study[J]. Mediators Inflamm，2017，2017：4327237. DOI：10.1155/2017/4327237.
[35]	KARACA Z，ISMAILOGULLARI S，KORKMAZ S，et al. Obstructive sleep apnoea syndrome is associated with relative hypocortisolemia and decreased hypothalamo-pituitary-adrenal axis response to 1 and 250 μg ACTH and glucagon stimulation tests[J]. Sleep Med，2013，14（2）：160-164. DOI：10.1016/j.sleep.2012.10.013.
[36]	ADEDAYO A M，OLAFIRANYE O，SMITH D，et al. Obstructive sleep apnea and dyslipidemia：evidence and underlying mechanism[J]. Schlaf Atmung，2014，18（1）：13-18. DOI：10.1007/s11325-012-0760-9.
[37]	WANG N，PENG Y J，SU X Y，et al. Histone deacetylase 5 is an early epigenetic regulator of intermittent hypoxia induced sympathetic nerve activation and blood pressure[J]. Front Physiol，2021，12：688322. DOI：10.3389/fphys.2021.688322.
[38]	CHEN Y C，HSU P Y，HSIAO C C，et al. Epigenetics：a potential mechanism involved in the pathogenesis of various adverse consequences of obstructive sleep apnea[J]. Int J Mol Sci，2019，20（12）：E2937. DOI：10.3390/ijms20122937.